IGC Pharma has added Hamilton Health Sciences (HHS) in Canada as a new clinical site for its ongoing, randomised Phase II CALMA trial of IGC-AD1 to treat agitation in Alzheimer’s disease. This ...

POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced additional positive interim results from its ongoing Phase 2 ...

IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In India, Highlights Important Milestones In Alzheimer's Research Nina Zdinjak Hedge Fund Settles At $2.25M With SEC For ...

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational ...

IGC Pharma (IGC) announced the expansion of its ongoing Phase 2 CALMA clinical trial with the addition of Butler Hospital’s Memory and Aging Program, a research center affiliated with the Warren ...

Shares of IGC Pharma, Inc. (NYSEMKT:IGC – Get Free Report) were down 7.4% on Thursday .The stock traded as low as $0.32 and last traded at $0.30. Approximately 214,616 shares changed hands ...

Zeit Aktuelle Nachrichten 08.04. IGC Pharma, Inc.: IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program POTOMAC, MARYLAND ...

IGC Pharma's CALMA Phase 2 trial is being conducted in the United States, and Canada, with a goal of enrolling 146 participants. The study aims to evaluate IGC-AD1's potential in reducing ...

POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial ...